l9n/ Pennsylvania

2019–2020 Regular Session

Senate Bill 675

An Act providing for certification of buprenorphine office-based prescribers; limiting the use of buprenorphine; and imposing powers and duties on the Department of Drug and Alcohol Programs.

Did not become law. It stopped in the House of Representatives's Human Services Committee on June 18, 2019. The 2019–2020 session has ended.

Sponsors

Who carried the bill in each chamber, and who signed on. Each name leads to the member's page.

Its course

May 28 to June 18, 2019, on one scale. In the top row each mark is a day something happened; taller marks are busier days.

Each committee stop sits inside its chamber.

Every action9 actions on 6 days

In the SenateMay 28 to Jun 1720 days

Health & Human ServicesMay 28 to Jun 47 days

AppropriationsJun 5 to Jun 105 days

In the House of RepresentativesJun 17 to Jun 18 · stopped1 day

Human ServicesJun 18 to Jun 18 · stopped0 days

Votes

Yeas to nays, as the General Assembly recorded them. Committee votes are set in.

  • Senate, third reading41–9

    Passed · Jun 17

Text

Each version as the General Assembly printed it.

l9n doesn't hold this bill's text yet.

What happened

In l9n's words, one line for each step. Every action as the General Assembly published it is below.

In the Senate May 28 – Jun 17

  1. Sent to HEALTH AND HUMAN SERVICES
  2. HEALTH AND HUMAN SERVICES recommended it
  3. Read a second time
  4. Sent to APPROPRIATIONS
  5. APPROPRIATIONS recommended it
  6. Passed the Senate, 41 to 9

In the House of Representatives Jun 18

  1. Arrived in the House of Representatives
  2. Sent to HUMAN SERVICES
All 9 actions, as published